Scott Tarriff - Feb 28, 2023 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Role: CEO, Director, 10%+ Owner
Signature: /s/ Scott Tarriff
Stock symbol: EGRX
Transactions as of: Feb 28, 2023
Transactions value $: -$87,164
Form type: 4
Date filed: 3/2/2023, 03:18 PM
Previous filing: Jan 24, 2023
Next filing: May 15, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EGRX	Common Stock	Tax liability	-$87.2K	-3.11K	-0.2%	$28.00	1.57M	Feb 28, 2023	Direct	F1
transaction	EGRX	Common Stock	Award	$0	+70.9K	+4.52%	$0.00	1.64M	Mar 1, 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The disposition reported on this Form 4 represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units.
F2	Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting of the unit. The shares issuable in respect of such RSUs shall vest with respect to 25% of the shares of common stock on each of the one, two, three and four-year anniversaries of March 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.

Content

The disposition reported on this Form 4 represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units.

Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting of the unit. The shares issuable in respect of such RSUs shall vest with respect to 25% of the shares of common stock on each of the one, two, three and four-year anniversaries of March 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.